Adding metastasis-directed therapy (MDT) to standard of care was tied to improvements in several survival endpoints in oligometastatic prostate cancer, a recent analysis suggests.

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

NHS staff are going on tour to raise awareness of prostate cancer. The Humber and North Yorkshire Cancer Alliance (HNYCA) is ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

Prostate cancer is one of the most common malignancies affecting men globally, usually developing within the prostate gland. While in its early stages, the disease is often confined to the gland ...